Periscope Capital’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Periscope Capital’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,000	Closed	-$44K	–	523
2023 Q3	$44K	Sell	200,000 -209,800	-51%	-$38.4K	0.01%	384
2023 Q2	$49.4K	Hold	409,800	–	–	﹤0.01%	431
2023 Q1	$19.7K	Hold	409,800	–	–	﹤0.01%	659
2022 Q4	$18.8K	Buy	409,800 +122,400	+43%	+$4.59K	﹤0.01%	692
2022 Q3	$16K	Hold	287,400	–	–	﹤0.01%	924
2022 Q2	$26K	Hold	287,400	–	–	﹤0.01%	864
2022 Q1	$103K	Hold	287,400	–	–	﹤0.01%	755
2021 Q4	$144K	Buy	+287,400	New	+$162K	﹤0.01%	755

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Periscope Capital's CLDI.WS Position: Q4 2023 in Review

Periscope Capital sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2023, closing a stake of 200,000 shares — an estimated $44K sold.

Periscope Capital first reported a position in CLDI.WS in Q4 2021 and held it in 8 quarters. The position peaked at $144K in Q4 2021. 17 funds tracked by Wall St. Rank hold CLDI.WS as of Q4 2023.

Periscope Capital reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2023 after selling out during the quarter.
Periscope Capital sold 200,000 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2023, an estimated $44K.
Periscope Capital first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 8 quarters.
Periscope Capital's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $144K in Q4 2021.
17 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2023.

Based on Periscope Capital's 13F filing for Q4 2023, filed 13 Feb 2024.